U.S. Markets open in 8 hrs 34 mins

The High Hope of Exelixis’s Cabometyx Label Expansion

Margaret Patrick

Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.